21世纪经济报道记者韩利明 国家医保局官微近日披露，中国裁判文书网公开的一份刑事判决书显示，某医药公司医药代表陆某为提 升个人销售业绩，篡改三名患者基因检测报告，致使不符合用药条件的患者使用肿瘤靶向药并报销医 保，造成医保基金损失。 判决书载明，陆某主要负责推广肺癌靶向药甲磺酸奥希替尼片，该药获批可用于经检测确认存在 EGFRT790M突变阳性的局部晚期或转移性非小细胞肺癌成人患者。但为完成销售指标，陆某在明知患 者EGFRT790M基因突变检测结果均为阴性、不符合用药条件的情况下，使用软件将患者报告中的"阴 性"结果篡改至"阳性"。 凭借虚假的阳性检测报告，患者在医院违规获得医保报销的奥希替尼，合计造成国家医保基金损失 27540元。经法院审理，最终判决陆某犯诈骗罪，判处有期徒刑八个月，并处罚金人民币七千元；退赔 在案的违法所得予以发还。 医保基金作为参保人的"救命钱"，对解决"看病贵、看病难"问题至关重要。然而，庞大的基金体量也让 部分利益相关方受利驱动铤而走险，骗保行为时有发生。从近年监管实践看，我国对医保骗保的打击已 日趋常态化、制度化，如何进一步筑牢基金安全防线，成为社会关注的关键。 乱象频现 事实 ...

Core Insights - AstraZeneca announced the approval of the combination therapy of Savolitinib (brand name: Worishe) and Osimertinib (brand name: Taris) by the National Medical Products Administration of China for treating locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) patients with EGFR gene mutations and MET amplification after progression on EGFR tyrosine kinase inhibitors (TKIs) [1][2] Group 1 - Savolitinib is the first selective MET inhibitor approved in China, developed in collaboration with Hutchison China MediTech, and is indicated for adult patients with locally advanced or metastatic NSCLC with MET exon 14 alterations [1] - Osimertinib is an irreversible third-generation EGFR-TKI with confirmed clinical activity in treating NSCLC patients, including those with central nervous system metastases [1][2] Group 2 - The approval is based on the SACHI Phase III clinical trial data, which achieved the predefined primary endpoint of progression-free survival (PFS) in a pre-specified interim analysis [2] - The combination therapy was included in the breakthrough therapy designation by the National Medical Products Administration in 2024 and received priority review for its new drug application in 2025 [2] - The approval marks the third indication for Savolitinib in China, highlighting its significance in addressing complex challenges in lung cancer treatment [2]